HomePTX • ASX
add
Prescient Therapeutics Ltd
Previous close
$0.038
Day range
$0.037 - $0.038
Year range
$0.037 - $0.11
Market cap
29.80M AUD
Avg Volume
380.90K
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Market news
Financials
Income Statement
Revenue
Net income
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 886.29K | 51.05% |
Operating expense | 2.49M | -11.37% |
Net income | -2.31M | -11.97% |
Net profit margin | -260.56 | 25.87% |
Earnings per share | — | — |
EBITDA | -1.60M | 27.86% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 14.51M | -33.78% |
Total assets | 20.39M | -27.45% |
Total liabilities | 2.33M | 14.40% |
Total equity | 18.07M | — |
Shares outstanding | 805.32M | — |
Price to book | 1.90 | — |
Return on assets | -19.63% | — |
Return on capital | -21.75% | — |
Cash Flow
Net change in cash
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -2.31M | -11.97% |
Cash from operations | -1.96M | 6.45% |
Cash from investing | 4.00M | 150.00% |
Cash from financing | 0.00 | -100.00% |
Net change in cash | 2.04M | 127.07% |
Free cash flow | -962.13K | 25.01% |
About
Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform, enhanced CAR-T cell manufacturing & function and on two small molecule drug targeted therapies. Wikipedia
Founded
May 22, 1986
Website
Employees
3
